Mid-term oncological outcomes of transanal total mesorectal excision for rectal cancer: a prospective, single center, randomized controlled trial

[Objectives] To compare mid-term oncological outcomes between transanal total mesorectal excision (taTME) and laparoscopic total mesorectal excision (lapTME) for rectal cancer. [Methods] This was a prospective randomized controlled trial of 68 patients with mid-and low rectal cancer admitted to the...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhu Yongfei, Yang Xuanhua, Teng Qing, Guo Qing, Fu Zhiyong, Fan Yushi, Huang Haixia, Jing Rong, Zhou Dongbing, Qin Long, Li Quanlin, Tian Yunhong, Kang Liang, Ren Mingyang
Format: Article
Language:zho
Published: Editorial Office of Journal of Colorectal & Anal Surgery 2022-12-01
Series:结直肠肛门外科
Subjects:
Online Access:https://jcas.gxmuyfy.cn/cn/wqll/paper.html?id=322&cateName=2022%E5%B9%B4%20%E7%AC%AC28%E5%8D%B7%20%E7%AC%AC6%E6%9C%9F
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850272564417396736
author Zhu Yongfei
Yang Xuanhua
Teng Qing
Guo Qing
Fu Zhiyong
Fan Yushi
Huang Haixia
Jing Rong
Zhou Dongbing
Qin Long
Li Quanlin
Tian Yunhong
Kang Liang
Ren Mingyang
author_facet Zhu Yongfei
Yang Xuanhua
Teng Qing
Guo Qing
Fu Zhiyong
Fan Yushi
Huang Haixia
Jing Rong
Zhou Dongbing
Qin Long
Li Quanlin
Tian Yunhong
Kang Liang
Ren Mingyang
author_sort Zhu Yongfei
collection DOAJ
description [Objectives] To compare mid-term oncological outcomes between transanal total mesorectal excision (taTME) and laparoscopic total mesorectal excision (lapTME) for rectal cancer. [Methods] This was a prospective randomized controlled trial of 68 patients with mid-and low rectal cancer admitted to the Nanchong Central Hospital—Affiliated Hospital of North Sichuan Medical College for planned radical surgery between December 2018 and April 2021. Patients were randomly assigned to the taTME group (n=33) and the lapTME group (n=35) using a random number table. One patient in the lapTME group was found during exploration to have peritoneal metastasis and excluded. The final study included 33 patients in the taTME group and 34 patients in the lapTME group. Pathology and follow-up data were collected and analyzed. Primary endpoints included two-year overall survival (OS), two-year disease-free survival (DFS), local recurrence, distant metastasis, and death. Secondary endpoint was pathology findings. [Results] No patients in either group showed positive distal resection margin or positive circumferential resection margin. The two groups did not differ significantly in terms of length of specimen, tumor length, distance between proximal and distal resection margin, distance between circumferential resection margin, grade of mesangial integrity, lymph node yield, T stage, N stage, and TNM stage (P>0.05). No patients were lost to follow-up. The Median follow-up was 31 (12, 40) months. Up to April 2022, no patients had local recurrence. One patient in the taTME group (3.0%) and one in the lapTME group (2.9%) was found to have lung metastasis at 18 and 19 months after surgery, respectively. No liver or other distant metastasis was reported. One patient in the taTME group died due to multiorgan failure caused by postoperative lung infection; one patient in the lapTME group had sudden death due to cardiac arrest at 1 month after surgery; no further death was reported during the follow-up period. The overall mortality rate was 3.0% in the taTME group and 2.9% in the lapTME group (P=1.000). Two-year OS was 97.0% in the taTME group and 97.1% in the lapTME group (P=0.986). Two-year DFS was 93.9% in the taTME group and 94.1% in the lapTME group (P=0.974). [Conclusion] TaTME is a safe and feasible treatment option for mid-and low rectal cancer. It can achieve comparable effectiveness and satisfactory mid-term oncological outcomes as lapTME.
format Article
id doaj-art-4049c8ddb51e4acaa0ec845dcc954a1a
institution OA Journals
issn 1674-0491
language zho
publishDate 2022-12-01
publisher Editorial Office of Journal of Colorectal & Anal Surgery
record_format Article
series 结直肠肛门外科
spelling doaj-art-4049c8ddb51e4acaa0ec845dcc954a1a2025-08-20T01:51:45ZzhoEditorial Office of Journal of Colorectal & Anal Surgery结直肠肛门外科1674-04912022-12-0128655155710.19668/j.cnki.issn1674-0491.2022.06.006Mid-term oncological outcomes of transanal total mesorectal excision for rectal cancer: a prospective, single center, randomized controlled trialZhu Yongfei0Yang Xuanhua1Teng Qing2Guo Qing3Fu Zhiyong4Fan Yushi5Huang Haixia6Jing Rong7Zhou Dongbing8Qin Long9Li Quanlin10Tian Yunhong11Kang Liang12Ren Mingyang13Department of Gastrointestinal Surgery, Nanchong Central Hospital—Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, ChinaDepartment of Gastrointestinal Surgery, Nanchong Central Hospital—Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, ChinaDepartment of Gastrointestinal Surgery, Nanchong Central Hospital—Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, ChinaDepartment of Gastrointestinal Surgery, Nanchong Central Hospital—Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, ChinaDepartment of Gastrointestinal Surgery, Nanchong Central Hospital—Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, ChinaDepartment of Gastrointestinal Surgery, Nanchong Central Hospital—Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, ChinaDepartment of Gastrointestinal Surgery, Nanchong Central Hospital—Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, ChinaDepartment of Gastrointestinal Surgery, Nanchong Central Hospital—Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, ChinaDepartment of Gastrointestinal Surgery, Nanchong Central Hospital—Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, ChinaDepartment of Gastrointestinal Surgery, Nanchong Central Hospital—Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, ChinaDepartment of Gastrointestinal Surgery, Nanchong Central Hospital—Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, ChinaDepartment of Gastrointestinal Surgery, Nanchong Central Hospital—Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, ChinaDepartment of Colorectal Surgery, the Sixth Affiliated Hospital of the Sun Yatsen University, Guangzhou 510655, Guangdong, ChinaDepartment of Gastrointestinal Surgery, Nanchong Central Hospital—Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, China[Objectives] To compare mid-term oncological outcomes between transanal total mesorectal excision (taTME) and laparoscopic total mesorectal excision (lapTME) for rectal cancer. [Methods] This was a prospective randomized controlled trial of 68 patients with mid-and low rectal cancer admitted to the Nanchong Central Hospital—Affiliated Hospital of North Sichuan Medical College for planned radical surgery between December 2018 and April 2021. Patients were randomly assigned to the taTME group (n=33) and the lapTME group (n=35) using a random number table. One patient in the lapTME group was found during exploration to have peritoneal metastasis and excluded. The final study included 33 patients in the taTME group and 34 patients in the lapTME group. Pathology and follow-up data were collected and analyzed. Primary endpoints included two-year overall survival (OS), two-year disease-free survival (DFS), local recurrence, distant metastasis, and death. Secondary endpoint was pathology findings. [Results] No patients in either group showed positive distal resection margin or positive circumferential resection margin. The two groups did not differ significantly in terms of length of specimen, tumor length, distance between proximal and distal resection margin, distance between circumferential resection margin, grade of mesangial integrity, lymph node yield, T stage, N stage, and TNM stage (P>0.05). No patients were lost to follow-up. The Median follow-up was 31 (12, 40) months. Up to April 2022, no patients had local recurrence. One patient in the taTME group (3.0%) and one in the lapTME group (2.9%) was found to have lung metastasis at 18 and 19 months after surgery, respectively. No liver or other distant metastasis was reported. One patient in the taTME group died due to multiorgan failure caused by postoperative lung infection; one patient in the lapTME group had sudden death due to cardiac arrest at 1 month after surgery; no further death was reported during the follow-up period. The overall mortality rate was 3.0% in the taTME group and 2.9% in the lapTME group (P=1.000). Two-year OS was 97.0% in the taTME group and 97.1% in the lapTME group (P=0.986). Two-year DFS was 93.9% in the taTME group and 94.1% in the lapTME group (P=0.974). [Conclusion] TaTME is a safe and feasible treatment option for mid-and low rectal cancer. It can achieve comparable effectiveness and satisfactory mid-term oncological outcomes as lapTME.https://jcas.gxmuyfy.cn/cn/wqll/paper.html?id=322&cateName=2022%E5%B9%B4%20%E7%AC%AC28%E5%8D%B7%20%E7%AC%AC6%E6%9C%9Frectal cancertransanal total mesorectal excisionlaparoscopic total mesorectal excisionmid-term oncological outcomes
spellingShingle Zhu Yongfei
Yang Xuanhua
Teng Qing
Guo Qing
Fu Zhiyong
Fan Yushi
Huang Haixia
Jing Rong
Zhou Dongbing
Qin Long
Li Quanlin
Tian Yunhong
Kang Liang
Ren Mingyang
Mid-term oncological outcomes of transanal total mesorectal excision for rectal cancer: a prospective, single center, randomized controlled trial
结直肠肛门外科
rectal cancer
transanal total mesorectal excision
laparoscopic total mesorectal excision
mid-term oncological outcomes
title Mid-term oncological outcomes of transanal total mesorectal excision for rectal cancer: a prospective, single center, randomized controlled trial
title_full Mid-term oncological outcomes of transanal total mesorectal excision for rectal cancer: a prospective, single center, randomized controlled trial
title_fullStr Mid-term oncological outcomes of transanal total mesorectal excision for rectal cancer: a prospective, single center, randomized controlled trial
title_full_unstemmed Mid-term oncological outcomes of transanal total mesorectal excision for rectal cancer: a prospective, single center, randomized controlled trial
title_short Mid-term oncological outcomes of transanal total mesorectal excision for rectal cancer: a prospective, single center, randomized controlled trial
title_sort mid term oncological outcomes of transanal total mesorectal excision for rectal cancer a prospective single center randomized controlled trial
topic rectal cancer
transanal total mesorectal excision
laparoscopic total mesorectal excision
mid-term oncological outcomes
url https://jcas.gxmuyfy.cn/cn/wqll/paper.html?id=322&cateName=2022%E5%B9%B4%20%E7%AC%AC28%E5%8D%B7%20%E7%AC%AC6%E6%9C%9F
work_keys_str_mv AT zhuyongfei midtermoncologicaloutcomesoftransanaltotalmesorectalexcisionforrectalcanceraprospectivesinglecenterrandomizedcontrolledtrial
AT yangxuanhua midtermoncologicaloutcomesoftransanaltotalmesorectalexcisionforrectalcanceraprospectivesinglecenterrandomizedcontrolledtrial
AT tengqing midtermoncologicaloutcomesoftransanaltotalmesorectalexcisionforrectalcanceraprospectivesinglecenterrandomizedcontrolledtrial
AT guoqing midtermoncologicaloutcomesoftransanaltotalmesorectalexcisionforrectalcanceraprospectivesinglecenterrandomizedcontrolledtrial
AT fuzhiyong midtermoncologicaloutcomesoftransanaltotalmesorectalexcisionforrectalcanceraprospectivesinglecenterrandomizedcontrolledtrial
AT fanyushi midtermoncologicaloutcomesoftransanaltotalmesorectalexcisionforrectalcanceraprospectivesinglecenterrandomizedcontrolledtrial
AT huanghaixia midtermoncologicaloutcomesoftransanaltotalmesorectalexcisionforrectalcanceraprospectivesinglecenterrandomizedcontrolledtrial
AT jingrong midtermoncologicaloutcomesoftransanaltotalmesorectalexcisionforrectalcanceraprospectivesinglecenterrandomizedcontrolledtrial
AT zhoudongbing midtermoncologicaloutcomesoftransanaltotalmesorectalexcisionforrectalcanceraprospectivesinglecenterrandomizedcontrolledtrial
AT qinlong midtermoncologicaloutcomesoftransanaltotalmesorectalexcisionforrectalcanceraprospectivesinglecenterrandomizedcontrolledtrial
AT liquanlin midtermoncologicaloutcomesoftransanaltotalmesorectalexcisionforrectalcanceraprospectivesinglecenterrandomizedcontrolledtrial
AT tianyunhong midtermoncologicaloutcomesoftransanaltotalmesorectalexcisionforrectalcanceraprospectivesinglecenterrandomizedcontrolledtrial
AT kangliang midtermoncologicaloutcomesoftransanaltotalmesorectalexcisionforrectalcanceraprospectivesinglecenterrandomizedcontrolledtrial
AT renmingyang midtermoncologicaloutcomesoftransanaltotalmesorectalexcisionforrectalcanceraprospectivesinglecenterrandomizedcontrolledtrial